Comparing Efficacy and Safety of Piperacillin/tazobactam and Amoxicillin/clavulanic acid in the Treatment of Complicated Urinary Tract Infections Efficacy and Safety of Piperacillin/tazobactam and Amoxicillin/clavulanic acid in the Treatment of UTIs
Novelty in Biomedicine,
Vol. 10 No. 3 (2022),
19 August 2022
,
Page 159-166
https://doi.org/10.22037/nbm.v10i3.37517
Abstract
Background: There has been an increasing concern regarding high morbidity and mortality rate among patients with severe and complicated urinary tract infections (UTIs) and their related complications. Hence, there is a great demand for choosing the best treatment protocol. In the study, we evaluated and compared the efficacy of piperacillin/tazobactam and amoxicillin/clavulanic acid for treating complicated urinary tract infections.
Materials and Methods: This study enrolled 42 patients suffering from UTIs referred to Labbafinezhad hospital, Tehran, Iran. Subjects were randomly assigned to receive intravenous piperacillin/tazobactam or intravenous amoxicillin/clavulanic acid. Clinical manifestations, vital signs, laboratory parameters, and drug side effects within three days of completing the treatment protocols were evaluated and compared between the two groups. Data analysis was performed using SPSS version 16.0. A P-value of less than 0.05 was considered significant.
Results: There was no significant difference in the frequency of pyuria and hematuria between the two groups before and after the intervention. The frequency of positive urine cultures for extended-spectrum beta-lactamase bacteria, Escherichia coli, was also similar between patient groups before intervention. However, a statistically significant difference in the rate of positive urine cultures for Klebsiella was found between the two groups. There was no significant difference between the two groups in terms of clinical signs and symptoms, including fever, dysuria, frequency, pain intensity, supra-pubic pain, or nausea and vomiting before the intervention, as well as within 72 hours after treatment. The vital signs were also similar between these two groups. No drug side effect was found among patients.
Conclusion: Blocking the function of orexin-A in the lactating rats decreased the expression of lipogenic mammary enzymes and serum insulin.
Conclusion: Using piperacillin/tazobactam or intravenous amoxicillin/clavulanic acid was effective and safe for treating complicated UTIs. Clinicians should consider the cost and availability of these drugs to choose the most appropriate treatment for the patients.
- Urinary tract infection, Antibiotic, Efficacy, Safety
How to Cite
References
Ahmed Al-Badr, Ghadeer Al-Shaikh. Recurrent Urinary Tract Infections Management in Women: A review. Sultan Qaboos Univ Med J. 2013;13(3):359–67.
Shelly J. Olin, Joseph W. Bartges. Urinary Tract Infections: Treatment/Comparative Therapeutics. Vet Clin North Am Small Anim Pract. 2015;45(4):721–46.
Hila Milo Rasouly, Weining Lu. Lower urinary tract development and disease Wiley Interdiscip Rev Syst Biol Med. Author manuscript; available in PMC 2014 May 1. Published in final edited form as: Wiley Interdiscip Rev Syst Biol Med. 2013;5(3):307–42.
Hickling DR, Sun TT, Wu XR. Anatomy and physiology of the urinary tract: relation to host defense and microbial infection. Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. 2017;1-25.
Dong Sup Lee, Seung-Ju Lee, Hyun-Sop Choe. Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance. Biomed Res Int. 2018; 2018: 7656752. Published online 2018.
Idan Yelin, Olga Snitser, Gal Novich, Rachel Katz, Ofir Tal, Miriam Parizade, Gabriel Chodick, Gideon Koren, Varda Shalev, Roy Kishony. Personal clinical history predicts antibiotic resistance of urinary tract infections Nat Med. Author manuscript; available in PMC 2020 Jan 16 .Published in final edited form as: Nat Med. 2019;25(7):1143-52.
Catherine L. Tooke, Philip Hinchliffe, Eilis C, Hirvonen, Yuiko Takebayashi, James Spencer, Bragginton, Charlotte K. Colenso, Viivi H.A. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. J Mol Biol. 2019;431(18):3472–500.
Hu YJ, Ogyu A, Cowling BJ, Fukuda K, Pang HH. Available evidence of antibiotic resistance from extended-spectrum β-lactamase-producing Enterobacteriaceae in paediatric patients in 20
countries: a systematic review and meta-analysis. Bulletin of the World Health Organization. 2019;97(7):486.
Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC infectious diseases. 2017;17(1):1-0.
Yu Bin Seo, Jacob Lee, Young Keun Kim, Seung Soon Lee, Jeong-a Lee, Hyo Youl Kim, Young Uh, Han-Sung Kim, Wonkeun Song. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2017;17:404.
Miri M, Fazeli M ,Amirpour A, Nasiri MJ, Pouriran R, Goudarzi MJGR. Emergence and spread of coagulase type III and staphylococcal cassette chromosome mec type IV among mupirocin-resistant Staphylococcus aureus isolated from wound infections. 2020;21:100858.
Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E, Benito N, et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect. 2013;9:962–8.
Verzasconi R, Rodoni P, Monotti R, Marone C, Mombelli G. Amoxicillin and clavulanic acid versus amoxicillin plus gentamicin in the empirical initial treatment of urinary tract infections in hospitalized patients. Schweiz Med Wochenschr. 1995;125(33):1533-9 .
Liu Y1, Zhang BL, Wang WH, Zhang X, Fan SY, Li L. Antibiotic resistance of pathogens isolated from 181 children with complicated urinary tract infection. Zhongguo Dang Dai Er Ke Za Zhi. 2011;13(5):381-4 .
Beytur A1, Yakupogullari Y2, Oguz F1, Otlu B2, Kaysadu H2. Oral amoxicillin-clavulanic Acid treatment in urinary tract infections caused by extended-spectrum Beta-lactamase-producing organisms. Jundishapur J Microbiol. 2014;8(1):e13792.
Dizbay M1, Özger HS2, Karaşahin Ö1, Karaşahin EF3. Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam. Turk J Med Sci. 2016;46(6):1760-4.
Naber KG1, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents. 2002;19(2):95-103.
- Abstract Viewed: 194 times
- pdf Downloaded: 319 times